<DOC>
	<DOCNO>NCT00069784</DOCNO>
	<brief_summary>The primary objective ORIGIN study : - To determine whether insulin glargine-mediated normoglycemia reduce cardiovascular morbidity and/or mortality people high risk vascular disease either Impaired Fasting Glucose ( IFG ) , Impaired Glucose Tolerance ( IGT ) early type 2 diabetes ; - To determine whether omega-3 fatty acid reduce cardiovascular mortality people IFG , IGT early type 2 diabetes . The secondary objective insulin glargine study determine insulin glargine-mediated normoglycemia reduce : - total mortality ( cause ) ; - risk diabetic microvascular outcome ; - rate progression IGT IFG type 2 diabetes .</brief_summary>
	<brief_title>The ORIGIN Trial ( Outcome Reduction With Initial Glargine Intervention )</brief_title>
	<detailed_description>The ORIGIN study conduct Population Health Research Institute Hamilton , Ontario ( Canada ) , work conjunction sponsor , independent Steering Committee . Routine visit occur 2 , 4 , 8 , 16 week follow randomization , every four month rest study , participants The duration study base number event observe ( event-driven study ) originally plan 5 year . In 2008-2009 ORIGIN 's follow-up extend approximately 2 year , publish literature complete study suggest long period effective glycemic contrast treatment might need see effect cardiovascular event .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : I1 . Individuals IFG and/or IGT , early diabetes , define . Glucose tolerance status determine 75 g oral glucose tolerance test ( OGTT ) perform fast ( ie , consumption food beverage water least 8 hour ) time screen candidate know diabetes . The qualify OGTT could obtain 4 week prior screen provide antidiabetic therapy ( ) remain unchanged qualify OGTT screen visit . Two plasma glucose value draw OGTT fast value ( FPG ) value draw two hour 75 g oral glucose load administer ( postprandial plasma glucose [ PPG ] ) . Impaired glucose tolerance ( IGT ) , define PPG value ≥140 &lt; 200 mg/dL ( ie , ≥7.8 &lt; 11.1 mmol/L ) , FPG &lt; 126 mg/dL ( 7.0 mmol/L ) . OR Impaired fasting glucose ( IFG ) , define FPG ≥110 &lt; 126 mg/dL ( ≥6.1 &lt; 7 mmol/L ) , without diabetes mellitus ( PPG must &lt; 200 mg/dL [ 11.1 mmol/L ] ) . OR Early type 2 diabetes , define FPG ≥126 mg/dL ( 7.0 mmol/L ) PPG ≥200 mg/dL ( 11.1 mmol/L ) , previous diagnosis diabetes , either : pharmacological treatment ( ambulatory ) least 10 week prior screen , screen glycated hemoglobin &lt; 150 % upper limit normal ( ULN ) laboratory ( eg , &lt; 9 % ULN 6 % ) take one oral antidiabetic drug ( OAD ) among sulfonylureas ( SU ) , biguanides , thiazolidinediones ( TZDs ) , alphaglucosidase inhibitor ( AGIs ) , meglitinides ( MGTs ) stable dose ambulatory least 10 week time screen ( 10 week prior hospitalization identify hospitalize CV event ) , screen glycated hemoglobin &lt; 133 % ULN laboratory ( eg , &lt; 8 % ULN 6 % ) take medication halfmaximum dose great , glycated hemoglobin &lt; 142 % ULN laboratory ( eg , &lt; 8.5 % ULN 6 % ) take medication less halfmaximum dose . Individuals take combination product contain two OADs eligible . I2 . Men woman age 50 year old I3 . At least one follow CV risk factor : previous myocardial infarction ( MI ) ( ≥ 5 day prior randomization ) previous stroke ( ≥ 5 day prior randomization ) previous coronary , carotid peripheral arterial revascularization angina document ischemic change ( least 2 mm ST segment depression electrocardiogram Graded Exercise Test [ GXT ] ; cardiac imaging study positive ischemia ) ; unstable angina document ischemic change ( either ST segment depression least 1 mm increase troponin normal range range diagnostic acute myocardial infarction ) microalbuminuria clinical albuminuria ( albumin : creatinine ratio ≥ 30 μg/mg least one time collection urine albumin excretion ≥20 μg/min ≥30 mg/24 hour total protein excretion ≥500 mg/24 hour ) leave ventricular hypertrophy electrocardiogram echocardiogram significant stenosis angiography coronary , carotid , low extremity artery ( ie , 50 % stenosis ) anklebrachial index &lt; 0.9 . I4 . Provision sign date informed consent prior study procedure . I5 . Ability willingness complete study diary questionnaires . I6 . Demonstrated ability use selfglucosemonitoring device , selfinject insulin prior randomization . I7 . A negative pregnancy test woman childbearing potential ( ie , ovulate , pre menopausal , surgically sterile ) agreement woman use reliable method birth control prevent pregnancy duration study . I8 . Willingness discontinue prior omega3 PUFA supplement duration study . Exclusion criterion E1 . Type 1 diabetes . E2 . Requiring ambulatory insulin treatment uncontrolled symptomatic hyperglycemia likely require addition ambulatory insulin therapy new antidiabetic agent either within 2 week randomization . E3 . Known antiglutamic acid decarboxylase antibody ( antiGAD Ab ) positivity past . E4 . Screening glycated hemoglobin ≥150 % ULN laboratory ( eg , ≥9 % ULN 6 % ) . E5 . Unwillingness inject insulin perform selfmonitoring blood glucose . E6 . Nonadherence runin requirement inject placebo insulin capillary glucose monitoring least 4 day prior randomization . E7 . Coronary artery bypass grafting ( CABG ) either planned time screening , CABG within 4 year prior screen however , participant angina , MI , stroke since previous CABG eligible randomization , even last CABG within 4 year . E8 . Serum creatinine &gt; 2.0 mg/dL ( 176 μmol/L ) screening . E9 . Active liver disease , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2.5 time ULN screening . E10 . Chronic recurrent treatment systemic corticosteroid , niacin treatment hyperlipidemia . E11 . Heart failure New York Heart Association ( NYHA ) Functional Class III IV . E12 . Expected survival &lt; 3 year nonCV cause cancer . E13 . Any factor likely limit protocol compliance report adverse event ( AEs ) . E14 . Unwilling unable discontinue TZDs . E15 . Simultaneous participation clinical trial active pharmacologic agent . E16 . Unwillingness permit sit contact primary physician communicate information study participant 's data treatment assignment . E17 . History hypersensitivity investigational product . E18 . Previous randomization study . E19 . A prior heart transplant , await heart transplant . E20 . Known infection human immunodeficiency virus ( HIV ) .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Impaired Fasting Glucose ( IFG )</keyword>
	<keyword>Impaired Glucose Tolerance ( IGT )</keyword>
</DOC>